A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 22 Sep 2017 Planned End Date changed from 1 Jun 2020 to 30 Apr 2020.
- 22 Sep 2017 Planned primary completion date changed from 1 Jun 2020 to 30 Apr 2020.
- 04 Sep 2017 New trial record